Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Public ClinicalTrials.gov record NCT00481689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa. The study doctor will give Cipro XR to some people to see if it is safe and works to treat complicated urinary tract infections caused by Pseudomonas aeruginosa. The study doctor will also gather information about using Cipro XR to treat complicated urinary tract infections caused by other bacteria. About 500 people with complicated urinary tract infections who are 18 years old and older will join this study. Cipro XR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections and acute uncomplicated pyelonephritis (inflammation of the kidney). The dose of Cipro XR used in this study (1000 mg a day for 7 to 14 days), has been shown to be safe and effective. This study is being done to gather more information on using this dose of Cipro XR for complicated urinary tract infections caused by Pseudomonas aeruginosa, as well as by other bacteria.
Study identification
- NCT ID
- NCT00481689
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 500 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Sep 2005 (Actual)
- Last update posted
- Jun 26, 2009
2004 – 2005
United States locations
- U.S. sites
- 35
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35206 | — |
| Not listed | Birmingham | Alabama | 35209 | — |
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | Scottsdale | Arizona | 85258 | — |
| Not listed | Cudahy | California | 90201 | — |
| Not listed | Fresno | California | 93720-0153 | — |
| Not listed | La Mesa | California | 91942-3058 | — |
| Not listed | Laguna Hills | California | 92653 | — |
| Not listed | Long Beach | California | 90806 | — |
| Not listed | Los Angeles | California | 90015 | — |
| Not listed | San Diego | California | 92103 | — |
| Not listed | Torrance | California | 90503 | — |
| Not listed | Waterbury | Connecticut | 06708 | — |
| Not listed | Ocala | Florida | 34474 | — |
| Not listed | Pembroke Pines | Florida | 33027 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Des Moines | Iowa | 50309 | — |
| Not listed | Iowa City | Iowa | 52242-1089 | — |
| Not listed | Watertown | Massachusetts | 02472 | — |
| Not listed | St Louis | Missouri | 63125 | — |
| Not listed | Las Vegas | Nevada | 89109 | — |
| Not listed | Reno | Nevada | 89511-2069 | — |
| Not listed | East Orange | New Jersey | 07918 | — |
| Not listed | Albuquerque | New Mexico | 87102 | — |
| Not listed | Albuquerque | New Mexico | 87109 | — |
| Not listed | Manhasset | New York | 11030-1961 | — |
| Not listed | North Massapequa | New York | 11758 | — |
| Not listed | Troy | New York | 12180-1695 | — |
| Not listed | Eugene | Oregon | 97401 | — |
| Not listed | Philadelphia | Pennsylvania | 19107-5096 | — |
| Not listed | Memphis | Tennessee | 38119 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Richmond | Virginia | 23249-0002 | — |
| Not listed | Tacoma | Washington | 98431-5000 | — |
| Not listed | Cheyenne | Wyoming | 82001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00481689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2009 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00481689 live on ClinicalTrials.gov.